

Sebastian M Jud

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6651521/publications.pdf>

Version: 2024-02-01

66
papers

2,796
citations

257101

24
h-index

174990

52
g-index

67
all docs

67
docs citations

67
times ranked

4981
citing authors

#	ARTICLE	IF	CITATIONS
1	Associations of Breast Cancer Risk Factors With Tumor Subtypes: A Pooled Analysis From the Breast Cancer Association Consortium Studies. <i>Journal of the National Cancer Institute</i> , 2011, 103, 250-263.	3.0	596
2	Genome-wide association studies identify four ER negative-specific breast cancer risk loci. <i>Nature Genetics</i> , 2013, 45, 392-398.	9.4	374
3	Circulating Micro-RNAs as Potential Blood-Based Markers for Early Stage Breast Cancer Detection. <i>PLoS ONE</i> , 2012, 7, e29770.	1.1	219
4	The Contributions of Breast Density and Common Genetic Variation to Breast Cancer Risk. <i>Journal of the National Cancer Institute</i> , 2015, 107, .	3.0	174
5	Low penetrance breast cancer susceptibility loci are associated with specific breast tumor subtypes: findings from the Breast Cancer Association Consortium. <i>Human Molecular Genetics</i> , 2011, 20, 3289-3303.	1.4	152
6	Common Breast Cancer Susceptibility Variants in <i>LSP1</i> and <i>RAD51L1</i> Are Associated with Mammographic Density Measures that Predict Breast Cancer Risk. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2012, 21, 1156-1166.	1.1	101
7	Ki-67 as a prognostic molecular marker in routine clinical use in breast cancer patients. <i>Breast</i> , 2009, 18, 135-141.	0.9	76
8	Characterizing mammographic images by using generic texture features. <i>Breast Cancer Research</i> , 2012, 14, R59.	2.2	65
9	BRCA mutations and their influence on pathological complete response and prognosis in a clinical cohort of neoadjuvantly treated breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2018, 171, 85-94.	1.1	56
10	Novel Associations between Common Breast Cancer Susceptibility Variants and Risk-Predicting Mammographic Density Measures. <i>Cancer Research</i> , 2015, 75, 2457-2467.	0.4	55
11	Mammographic density as a risk factor for breast cancer in a German case-control study. <i>European Journal of Cancer Prevention</i> , 2011, 20, 1-8.	0.6	53
12	Breast Volumetry Using a Three-Dimensional Surface Assessment Technique. <i>Aesthetic Plastic Surgery</i> , 2011, 35, 847-855.	0.5	50
13	Association of mammographic density with hormone receptors in invasive breast cancers: Results from a case-only study. <i>International Journal of Cancer</i> , 2012, 131, 2643-2649.	2.3	44
14	Genetic Predisposition to In Situ and Invasive Lobular Carcinoma of the Breast. <i>PLoS Genetics</i> , 2014, 10, e1004285.	1.5	39
15	Risk, Prediction and Prevention of Hereditary Breast Cancer - Large-Scale Genomic Studies in Times of Big and Smart Data. <i>Geburtshilfe Und Frauenheilkunde</i> , 2018, 78, 481-492.	0.8	38
16	Association of mammographic density with the proliferation marker Ki-67 in a cohort of patients with invasive breast cancer. <i>Breast Cancer Research and Treatment</i> , 2012, 135, 885-892.	1.1	36
17	Prognostic effect of Ki-67 in common clinical subgroups of patients with HER2-negative, hormone receptor-positive early breast cancer. <i>Breast Cancer Research and Treatment</i> , 2019, 175, 617-625.	1.1	35
18	TILGen: A Program to Investigate Immune Targets in Breast Cancer Patients - First Results on the Influence of Tumor-Infiltrating Lymphocytes. <i>Breast Care</i> , 2018, 13, 8-14.	0.8	32

#	ARTICLE	IF	CITATIONS
19	The Hohl instrument for optimizing total laparoscopic hysterectomy: results of more than 500 procedures in a university training center. Archives of Gynecology and Obstetrics, 2012, 285, 123-127.	0.8	31
20	Filtration based assessment of CTCs and CellSearch® based assessment are both powerful predictors of prognosis for metastatic breast cancer patients. BMC Cancer, 2018, 18, 204.	1.1	30
21	Polymorphism in <i>HTR3D</i> shows different risks for acute chemotherapy-induced vomiting after anthracycline chemotherapy. Pharmacogenomics, 2010, 11, 943-950.	0.6	29
22	Hormone replacement therapy and prognosis in ovarian cancer patients. European Journal of Cancer Prevention, 2013, 22, 52-58.	0.6	28
23	The PI3K Pathway: Background and Treatment Approaches. Breast Care, 2016, 11, 398-404.	0.8	28
24	Breast cancer risk assessment in a mammography screening program and participation in the IBIS-II chemoprevention trial. Breast Cancer Research and Treatment, 2010, 121, 101-110.	1.1	26
25	Pain perception and detailed visual pain mapping in breast cancer survivors. Breast Cancer Research and Treatment, 2010, 119, 105-110.	1.1	24
26	Gynecologic oncologists' attitudes and practices relating to integrative medicine: results of a nationwide AGO survey. Archives of Gynecology and Obstetrics, 2017, 296, 295-301.	0.8	24
27	Prognostic relevance of Ki-67 in the primary tumor for survival after a diagnosis of distant metastasis. Breast Cancer Research and Treatment, 2013, 138, 899-908.	1.1	23
28	Assessment of mammographic density before and after first full-term pregnancy. European Journal of Cancer Prevention, 2010, 19, 405-412.	0.6	21
29	FemZone trial: a randomized phase II trial comparing neoadjuvant letrozole and zoledronic acid with letrozole in primary breast cancer patients. BMC Cancer, 2014, 14, 66.	1.1	19
30	Knowledge and attitudes regarding medical research studies among patients with breast cancer and gynecological diseases. BMC Cancer, 2015, 15, 587.	1.1	19
31	Mammographic density is the main correlate of tumors detected on ultrasound but not on mammography. International Journal of Cancer, 2016, 139, 1967-1974.	2.3	19
32	Association between breast cancer risk factors and molecular type in postmenopausal patients with hormone receptor-positive early breast cancer. Breast Cancer Research and Treatment, 2019, 174, 453-461.	1.1	15
33	HLA-G and HLA-F protein isoform expression in breast cancer patients receiving neoadjuvant treatment. Scientific Reports, 2020, 10, 15750.	1.6	15
34	Relevance of Health Economics in Breast Cancer Treatment - the View of Certified Breast Centres and Their Patients. Breast Care, 2013, 8, 15-21.	0.8	14
35	Low-dose methotrexate treatment in ectopic pregnancy: a retrospective analysis of 164 ectopic pregnancies treated between 2000 and 2008. Archives of Gynecology and Obstetrics, 2014, 289, 329-335.	0.8	14
36	Association of molecular subtypes with breast cancer risk factors. European Journal of Cancer Prevention, 2015, 24, 484-490.	0.6	14

#	ARTICLE	IF	CITATIONS
37	Inhibition of hyperalgesia by conditioning electrical stimulation in a human pain model. <i>Pain</i> , 2011, 152, 1298-1303.	2.0	13
38	Correlation of mammographic density and serum calcium levels in patients with primary breast cancer. <i>Cancer Medicine</i> , 2017, 6, 1473-1481.	1.3	13
39	Macromastia: an economic burden? A disease cost analysis based on real-world data in Germany. <i>Archives of Gynecology and Obstetrics</i> , 2021, 303, 521-531.	0.8	13
40	Mammographic density and prognosis in primary breast cancer patients. <i>Breast</i> , 2021, 59, 51-57.	0.9	13
41	Assessment of breast volume changes during human pregnancy using a three-dimensional surface assessment technique in the prospective CGATE study. <i>European Journal of Cancer Prevention</i> , 2014, 23, 151-157.	0.6	12
42	Association between mammographic density and pregnancies relative to age and BMI: a breast cancer case-only analysis. <i>Breast Cancer Research and Treatment</i> , 2017, 166, 701-708.	1.1	12
43	Financing of certified centers: a willingness-to-pay analysis. <i>Archives of Gynecology and Obstetrics</i> , 2013, 287, 495-509.	0.8	11
44	Comprehensive visualization of paresthesia in breast cancer survivors. <i>Archives of Gynecology and Obstetrics</i> , 2014, 290, 135-141.	0.8	11
45	Initial clinical results with a fusion prototype for mammography and three-dimensional ultrasound with a standard mammography system and a standard ultrasound probe. <i>Acta Radiologica</i> , 2018, 59, 1406-1413.	0.5	10
46	Factors influencing breast changes after pregnancy. <i>European Journal of Cancer Prevention</i> , 2013, 22, 259-261.	0.6	9
47	A Standard Mammography Unit " Standard 3D Ultrasound Probe Fusion Prototype: First Results. <i>Geburtshilfe Und Frauenheilkunde</i> , 2017, 77, 679-685.	0.8	9
48	Assessment of the additional clinical potential of X-ray dark-field imaging for breast cancer in a preclinical setup. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592095793.	1.4	9
49	Correlates of mammographic density in B-mode ultrasound and real time elastography. <i>European Journal of Cancer Prevention</i> , 2012, 21, 343-349.	0.6	8
50	Breast MRI texture analysis for prediction of BRCA-associated genetic risk. <i>BMC Medical Imaging</i> , 2020, 20, 86.	1.4	8
51	Logbooks alone are not enough: initial experience with implementing a logbook for medical students in a clinical internship in gynecology and obstetrics. <i>European Journal of Medical Research</i> , 2020, 25, 15.	0.9	8
52	Introducing multiple-choice questions to promote learning for medical students: effect on exam performance in obstetrics and gynecology. <i>Archives of Gynecology and Obstetrics</i> , 2020, 302, 1401-1406.	0.8	7
53	Visual pain mapping in endometriosis. <i>Archives of Gynecology and Obstetrics</i> , 2012, 286, 687-693.	0.8	6
54	Using automated texture features to determine the probability for masking of a tumor on mammography, but not ultrasound. <i>European Journal of Medical Research</i> , 2017, 22, 30.	0.9	6

#	ARTICLE	IF	CITATIONS
55	Analysis of motives and patient satisfaction in oncological second opinions provided by a certified university breast and gynecological cancer center. Archives of Gynecology and Obstetrics, 2020, 301, 1299-1306.	0.8	6
56	Diagnostic Accuracy of Breast Medical Tactile Examiners (MTEs): A Prospective Pilot Study. Breast Care, 2019, 14, 41-47.	0.8	5
57	RANKL and OPG and their influence on breast volume changes during pregnancy in healthy women. Scientific Reports, 2020, 10, 5171.	1.6	5
58	Should Breast Cancer Surgery Be Done in an Outpatient Setting?. Geburtshilfe Und Frauenheilkunde, 2017, 77, 879-886.	0.8	3
59	Using Probability for Pathological Complete Response (pCR) as a Decision Support Marker for Neoadjuvant Chemotherapy in HER2 Negative Breast Cancer Patients – a Survey Among Physicians. Geburtshilfe Und Frauenheilkunde, 2018, 78, 707-714.	0.8	3
60	Analysis of Oncological Second Opinions in a Certified University Breast and Gynecological Cancer Center in Relation to Complementary and Alternative Medicine. Complementary Medicine Research, 2020, 27, 431-439.	0.5	3
61	Clinical and Preclinical Experience with Gefitinib and Sunitinib. Breast Care, 2007, 2, 68-73.	0.8	2
62	Analysis of Oncological Second Opinions in a Certified University Breast and Gynecological Cancer Center Regarding Consensus between the First and Second Opinion and Conformity with the Guidelines. Breast Care, 2021, 16, 291-298.	0.8	2
63	Discordance between Primary Breast Cancer and Ipsilateral Breast Cancer Tumor Recurrence as a Function of Distance. Journal of Clinical Medicine, 2020, 9, 4033.	1.0	1
64	Influence of Family History of Breast or Ovarian Cancer on Pathological Complete Response and Long-Term Prognosis in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy. Breast Care, 2021, 16, 254-262.	0.8	0
65	Is Reduction Mammoplasty Cost-Effective? A Cost-Utility Analysis of Surgical Treatment for Macromastia in Germany. Breast Care, 2021, 16, 1-9.	0.8	0
66	Abstract 940: The contribution of common breast cancer susceptibility loci to the breast density and breast cancer association and the Breast Cancer Surveillance Consortium (BCSC) risk model. , 2014, , .		0